We are a global biopharmaceutical company committed to developing
drugs for the treatment of a range of severe skin disorders.
CLINUVEL has taken a keen interest and active role in research and development in photomedicine, investigating the interaction of light and human biology and pioneering the concept of medicinal photoprotection – protecting skin from light.
As pioneers and leaders in understanding the interaction of light and human biology, CLINUVEL’s products have been developed after years of extensive scientific research and understanding of rare disorders.
As pioneers in medicinal photoprotection, we are continually striving to expand our deep reservoir of knowledge and expertise within the broader field of photocare.
CLINUVEL takes pride in connecting with as many people as possible online. Join us on any of our social channels to keep up to date for latest company developments.
CLINUVEL’s Investor Area contains a range of information for investors including latest announcements, share price information and answers to frequently asked questions.Learn more
CLINUVEL is listed on the Australian Securities Exchange under the ticker code CUV.
28 January 2016
Enclosed is a copy of the Quarterly report for entities admitted on the basis of commitments.
Download PDF for more